ArticleBMC microbiology2026
One-pot LAMP-CRISPR/Cas12b coupled with nanoparticle-based biosensor for point-of-care test of Neisseria gonorrhoeae.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGonorrhea, caused by the human obligate pathogen Neisseria gonorrhoeae, is the second most common bacterial sexually transmitted infection worldwide. In the absence of an effective gonococcal vaccine, convenient and accurate diagnosis of N. gonorrhoeae infection is essential for optimal patient management and for interrupting ongoing transmission.
methodsA custom-designed gold nanoparticle-based lateral flow biosensor (AuNP-LFB) was employed. The unique LAMP primers and a specific single-guide RNA (sgRNA) were designed to target the orf1 gene of N. gonorrhoeae. The key diagnostic conditions, including detection temperature and time, were optimized. The sensitivity and specificity of the assay were validated, and its clinical feasibility was validated using seventy-eight genital secretion samples from patients suspected of N. gonorrhoeae infection.
resultsThe custom-designed AuNP-LFB was successfully fabricated. The Ng-CRISPR-One-Pot assay achieved a limit of detection (LoD) as low as 7 copies per test and exhibits no cross-reactivity with other tested microbial species. The entire detection workflow, including nucleic acid extraction (10 min), LAMP-CRISPR/Cas12b detection (56 °C, 50 min), and AuNP-LFB visual readout (< 2 min), can be completed within 65 min without requiring specialized instrumentation. Compared with a reference N. gonorrhoeae-qPCR method, our assay achieved 100% sensitivity (95% CI: 93.94-100.00%) and 100% specificity (95% CI: 82.35-100.00%).
conclusionsCollectively, these preliminary results indicate that the Ng-CRISPR-One-Pot assay holds promise as a practical point-of-care (POC) diagnostic tool, enabling accurate and convenient detection of N. gonorrhoeae, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.